Cumulus Neuroscience

Cumulus Neuroscience is a private, Belfast-based company providing a sophisticated digital biomarker platform for central nervous system (CNS) disorders. Its core product, NeuLogiq®, combines a proprietary EEG headset, validated digital cognitive tasks, and machine learning analytics to enable frequent, at-home, longitudinal monitoring of patients in clinical trials and healthcare settings. The company operates a platform-as-a-service business model, targeting pharmaceutical partners to improve trial efficiency and outcome measurement, and is supported by a unique paid-in Pharma Advisory Group (CPAG) consortium.

NeuLogiq®: An integrated, at-home, medical-grade platform combining a 510(k)-cleared EEG headset, tablet-based digital cognitive assessments, third-party modules (facial expression, speech analysis, sleep), and proprietary AI/ML analytics for longitudinal brain function monitoring.

Competitors include other digital biomarker companies like Altoida, Winterlight Labs (acquired by Holmusk), and Cogstate, as well as larger medical device firms (e.g., Medtronic, Philips) and CROs developing decentralized trial solutions. Cumulus differentiates with its integrated, medical-grade EEG hardware and its unique paid-in pharma consortium model.